Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• RNA interference (RNAi) using small interfering RNA (siRNA) shows promise for cancer treatment by regulating oncogenes.
• A major challenge for clinical siRNA application is achieving safe and effective delivery into target cancer cells.
• Lipid-based delivery systems, particularly lipid nanoparticles (LNPs), are crucial for protecting siRNA and facilitating cellular uptake.

Purpose of the Study:

• To review recent advancements in environment-responsive lipids and nanoparticles for siRNA delivery in cancer therapy.
• To highlight the potential of novel lipid systems in overcoming current siRNA delivery limitations.
• To discuss the clinical translation prospects of these innovative delivery strategies.

Main Methods:

• Focus on environment-responsive lipids, including protonatable/ionizable amino lipids, switchable lipids, and pH-sensitive multifunctional amino lipids.
• Discussion of environment-responsive lipid/siRNA nanoparticles (ERLNPs) designed for enhanced cytosolic delivery.
• Summary of preclinical studies evaluating ERLNPs for targeted gene silencing in cancer cells.

Main Results:

• Environment-responsive lipids demonstrate the ability to adapt to delivery environments, improving intracellular siRNA release.
• ERLNPs show efficacy in preclinical models for delivering therapeutic siRNA to the cytoplasm of cancer cells.
• These novel lipids facilitate efficient gene silencing of target oncogenes, supporting cancer treatment.

Conclusions:

• Environment-responsive lipids represent a significant breakthrough in overcoming siRNA delivery barriers for cancer therapy.
• ERLNPs hold great promise for clinical translation due to their enhanced efficacy and safety profiles.
• Continued research into these advanced lipid systems is crucial for advancing siRNA-based cancer treatments.